Graduate Theses, Dissertations, and Problem Reports
2011

Phosphodiesterase-4 in the Brain: Effects of Pharmacological
Inhibition and Mutation of DISC1
Lan Xiao
West Virginia University

Follow this and additional works at: https://researchrepository.wvu.edu/etd

Recommended Citation
Xiao, Lan, "Phosphodiesterase-4 in the Brain: Effects of Pharmacological Inhibition and Mutation of
DISC1" (2011). Graduate Theses, Dissertations, and Problem Reports. 4818.
https://researchrepository.wvu.edu/etd/4818

This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses,
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU.
For more information, please contact researchrepository@mail.wvu.edu.

Phosphodiesterase-4 in the Brain: Effects of Pharmacological Inhibition and
Mutation of DISC1
Lan Xiao
Dissertation submitted to the
School of Pharmacy
at West Virginia University
in partial fulfillment of the requirements
for the degree of
Doctor of Philosophy
in
Pharmaceutical and Pharmacological Sciences
James M. O’Donnell, Ph.D., Chair
Patrick S. Callery, Ph.D.
Han-Ting Zhang, M.D., Ph.D.
James O’Callaghan, Ph.D.
Jason D. Huber, Ph.D.
Department of Basic Pharmaceutical Sciences
Morgantown, West Virginia
2011

Keywords:phosphodiesterase-4, cyclic adenosine monophosphate, protein kinase A,
cyclic AMP response element binding protein, forced-swim test, high-affinity
rolipram binding state, low-affinity rolipram binding state, disrupted in
schizophrenia 1, upstream conserved region
Copyright 2011 Lan Xiao

Abstract

Phosphodiesterase-4 in the Brain: Effects of Pharmacological Inhibition and
Mutation of DISC1
Lan Xiao
The effects of treatment with PDE4 inhibitors on cAMP/pCREB signaling,
hippocampal neurogenesis and immobility in forced-swim test and the effects of DISC1
mutation on cAMP/pCREB signaling, PDE4 subtypes and PDE4 activity and highaffinity rolipram binding state were determined. Acute treatment with PDE4 inhibitors
increased cAMP and pCREB transiently, as determined by ELISA and Western blotting,
respectively. Repeated treatment with PDE4 inhibitors for 16 days produced
antidepressant-like effect as evidence by decreased immobility in forced-swim test,
increased cAMP/pCREB signaling and enhanced hippocampal neurogenesis. PDE4
inhibitors which preferentially interact with the high-affinity rolipram binding state, such
as rolipram and piclamilast, produced greater effects than CDP840, which preferentially
interacts with the low-affinity rolipram binding state.
PDE4 exerts its normal functions by interacting with a variety of binding proteins.
The effects of mutation of one of the most important binding proteins DISC1, a risk
factor gene for mental disorders, were determined. In this study, DISC1 mutant mice that
carried truncated DISC1 proteins were used. DISC1 mutation increased cAMP and
pCREB levels, and decreased PDE4 activity in prefrontal cortex, hippocampus and
striatum. The PDE4B1, B3 and B4 splice variants were decreased in these three brain
regions, while the D3 and D5 variants were decreased only in the hippocampus; PDE4A1
and A5 splice variants were not affected by the DISC1 mutation. Previous work has
shown greater DISC1 association with the PDE4B subtype than the other subtypes.
Radioligand binding assays showed that the high affinity rolipram binding state was
decreased in brain regions of DISC1 mutant mice, suggesting high affinity rolipram
binding state is functionally associated with DISC1.
Overall, PDE4 inhibitors which preferentially interact with the high-affinity rolipram
binding states produced greater effects on cAMP/pCREB and behavior, as well as for
increasing hippocampal neurogenesis. In addition, DISC1 mutation decreased PDE4
activity and upregulated cAMP/pCREB levels. These suggest DISC1 is important for the
normal function of PDE4 and downstream cAMP signaling. Mutation of DISC1 also
induced a decrease in PDE4B and PDE4D, but not PDE4A splice variants. The studies
shed light on the understanding of the function of high-affinity rolipram binding state in
the central nervous system and may provide a new target for antidepressant drug
discovery and development.
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Chapter 1
Introduction

1

1.1 Symptoms of Depression
Depression was first termed as melancholia, which means black bile in Greek, by
Hippocrates (Akiskal, 2000). To date, depression is one of the most prevalent forms of
mental illness in the world. Severe form of depression influences about 2%-5% of the
U.S. population and mild form of depression affects up to 20% of the population (Nestler
et al., 2002). In addition, due to the high risk of suicide, depression is a very life
threatening disease (Blazer, 2000). Though the symptomatology of depression has been
described, the pathophysiology of this disorder was not understood very well until the
middle of the 19th century (Nestler et al., 2002). In 1960, depression was defined as
major depression based on the symptomatic criteria of Diagnostic and Statistical Manual
and this categorization has continued (DSMIV, 2000). This criteria include: depressed
mood; irritability; low self esteem; feelings of hopelessness, worthlessness, and guilt;
decreased ability to concentrate or think; change of appetite or weight; change of sleep
habits; low energy; fatigue or increased agitation; decreased interest in pleasurable
activities; and recurrent thinking of death or suicide. When a number of symptoms last
for longer than 2 weeks and normal social and occupational functions are impaired, major
depression is diagnosed (DSMIV, 2000).

1.2 Neurobiology of Depression
Current thinking is that genetic and non-genetic factors contribute to the
development of depression. Though no single genes have been identified to be highly
related to depression in a conclusive manner, approximately 40-50% of the risk for
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depression is genetic (Fava and Kendler, 2000). Because a variety of genes contribute to
the development of depression, identifying a single risk gene and its effects becomes very
difficult. In addition, non-genetic factors such as stress, emotional stimuli, or viral
infection might also induce the development of the depression (Burmeister, 1999).
Generally, depression is described as a stress-related disorder. However, stress alone is
not sufficient to induce depression and most people who experience serious stress do not
become depressed. This indicates that interaction between genetic predisposition and
environmental factors contribute to the pathogenesis of depression (Nestler et al., 2002).
To date, the neurobiology of depression could be explained by several mechanisms:
dysfunction of the hippocampus and hypothalamic-pituitary-adrenal axis; impairment of
neurotrophic mechanisms; and impairment of brain reward pathways. In the theory of
regulation of the hypothalamus-pituitary-adrenal axis, parvocellular neurons that contain
corticotrophin-releasing factor (CRF) of the paraventricular nucleus of the hypothalamus
integrate input induced by stress. These inputs include excitatory afferents from the
amygdala, inhibitory afferents from the hippocampus, and inputs from the ascending
monoamine pathways. CRF is released from neurons located in the hypophyseal portal
system and exerts its effects on the anterior pituitary to facilitate the release of ACTH.
ACTH increases glucocorticoid levels, while simultaneously, inhibiting the synthesis of
CRF and ACTH.

However, a high level of glucocorticoids damages hippocampal

function, initiating a hypercortisolemic state associated with depression (Nestler et al.,
2002). Despite the dysfunction of the hypothalamus-pituitary-adrenal axis having been
associated with depression, it is still unknown whether it is the cause for depression or
secondary to depression (Nestler et al., 2002).
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Another hypothesis based on the pathologic effects of stress on the hippocampus
involves the role of the neurotrophic factor in the etiology of depression. Neurotrophic
factors are found to regulate neural growth and differentiation during development, as
well as plasticity and survival of adult neurons and glial cells (Duman et al., 1997; Altar,
1999). The neurotrophic hypothesis states that a deficiency of neurotrophic factors
contributes to hippocampal pathology during the development of depression (Nestler et
al., 2002). Chronic stress decreases BDNF expression in the dentate gyrus and the
pyramidal cell layers of the hippocampus (Smith et al., 1995). This decrease may result
partly from a reduction in glucocorticoids (Smith et al., 1995) and a change in
serotonergic transmission (Vaidya et al., 1997).

In addition, chronic antidepressant

treatment enhances BDNF expression (Nibuya et al., 1995). Compelling studies reveal
that severe stress induces changes in glutamatergic and monoaminergic neurons; these
changes include the reduction of dendritic arborizations and BDNF expression. The
reduction of BDNF is due to excessive glucocorticoid-induced reduction of transcription
via CREB, which controls BDNF expression (Kuroda and McEwen, 1998).
Antidepressant treatments produce the opposite effects, i.e., increased dendritic
arborization and BDNF expression in the hippocampus via activation of CREB (Conti et
al., 2002). In vivo and in vitro, expression of BDNF is increased by CREB (Tao et al.,
1998; Conti et al., 2002). Injection of CREB into hippocampal dentate gyrus increases
CREB activity, and exerts an antidepressant-like effect in forced swim and learned
helplessness tests (Chen et al., 2001).
Most preclinical studies have focused on the hippocampus because of its role in the
memory and spatial learning.

Recently, brain imaging and autopsy studies indicate
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abnormalities in several other brain regions in patients with depression such as nucleus
accumbens, hypothalamus and amygdala (Nestler et al., 2002).

Such regions are

involved in the brain reward pathway. The nucleus accumbens is part of the mesolimbic
dopamine system, which contains dopaminergic neurons. Dopaminergic neurons in the
nucleus accumbens play an important role in reward (Nestler et al., 2002). Drugs of
abuse exert their rewarding effects via enhancing dopaminergic transmissions (Wise,
1996; Koob et al., 1998). Other drugs such as opiates not only activate dopaminergic
neurons, but also  opioid receptors in the nucleus accumbens (Nestler et al., 2002). The
possible involvement of the nucleus accumbens in the development of depression has
been studied for decades. Behavioral studies demonstrate drugs of abuse decrease the
stimulation threshold for intracranial self-stimulation (Hall et al., 1977; Wise, 1996). The
reinforcing effects of drugs of abuse depend in part on their ability to activate CREB in
the nucleus accumbens (Berke and Hyman, 2000; Nestler, 2001; Shaw-Lutchman et al.,
2002). An increase of CREB in the region decreases the sensitivity to a variety of
aversive stimulants, while a decrease of CREB increases that sensitivity (Carlezon et al.,
1998). Acute and chronic stress could increase the CREB-mediated transcription in the
nucleus accumbens (Carlezon et al., 1998; Pliakas et al., 2001). Thus, it would appear
that CREB in the nucleus accumbens is involved in the behavioral responses to the
stimulants (Nestler et al., 2002). Several studies point out that dynorphin is a target gene
downstream of the CREB signaling cascade, which may affect sensitivity to aversive
stimuli and contribute to some symptoms of depression (Carlezon et al., 1998; Pliakas et
al., 2001).

In addition, BDNF in the nucleus accumbens significantly enhances drug-

reward signaling (Horger et al., 1999).
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Besides the nucleus accumbens, the hypothalamus is also regarded as contributing to
the pathogenesis of depression. Orexin, which is expressed in the lateral hypothalamus,
regulates both sleep and eating activity (Willie et al., 2001). Melanin, which is expressed
in the lateral hypothalamus, modulates sexual and anxiety-like behaviors (Gonzalez et al.,
1996; Ahima and Osei, 2001; Monzon et al., 2001). Melanocortin, which is expressed in
the medial hypothalamus, regulates the anxiety-like behavior (Nestler et al., 2002).
Furthermore, the amygdala is also involved in the molecular mechanism of depression
due to its role in conditioned fear (Davis, 1998; Cahill et al., 1999), drug abuse, and
natural rewards (Everitt et al., 1999; Koob, 1999; Hall et al., 2001; Josselyn et al., 2001;
Jentsch et al., 2002).

1.3 Animal Models of Depression
Animal models have been important in studying neural factors involved in
depression as well as the mechanism of action of antidepressant drugs. However, there is
no single animal model that fully captures the various aspects of depression in humans.
The cardinal symptoms of depression such as feelings of worthless and suicidal ideation
exhibited in humans are difficult or impossible to model in animals (Nestler et al., 2002).
Thus, the measurements of depression-related behavior in laboratory animals depend
primarily on two criteria, i.e., responses to antidepressants and responses to stress
(Willner, 1995; Hitzemann, 2000; Porsolt, 2000; Lucki, 2001). Though there are many
limitations with the animal models described as Table 1.1, overall they are useful for
studying the effects of new medications and the neurobiological mechanisms underlying
depression (Nestler et al., 2002).
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Table 1.1. Animal Models Use for Depression/Antidepressant Research
Model

Animals

Antidepressant effects

Forced swim

Rat, Mouse

Decrease the time of immobility
(Rodgers and Dalvi, 1997; Page
et al., 1999; Zhang et al., 2002)

Tail suspension

Mouse

Decrease the time of immobility
(Rodgers and Dalvi, 1997; Zhang
et al., 2002)

Learned helplessness

Rat, Mouse

Decrease escape latency and
failures (Hajszan et al., 2009)

Olfactory bulbectomy

Rat, Mouse

Partially

reverse

behavioral

abnormalities induced by lesion
(Breuer et al., 2009)
Social defeat stress

Rat, Mouse

Increase the time spent in the
interaction zone (Brown et al.,
2011)

Chronic mild stress

Rat, Mouse

Reverse

changes

consumption,

in

sucrose

corticosterone

level (Willner et al., 1987; Li et
al., 2007)
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Maternal deprivation

Rat, Mouse

Decrease

the

HPA

responsiveness,
behaviors

axis
anxiety

and

alcohol

consumption (Huot et al., 2001)
Differential reinforcement of Rats, Mouse

Decrease

response

low rate (DRL)

increase

reinforcement

rate

and
rate

(O'Donnell and Seiden, 1983;
van Hest et al., 1992)

8

1.4 Treatment of Depression
There are several antidepressant treatments effective for patients with depression.
Older treatments include electroconvulsive seizures, tricyclic antidepressants (TCAs),
and monoamine oxidase inhibitors (MAOIs). The original tricyclic antidepressants, e.g.,
imipramine, arose from research on the behavioral effects of antihistamines, while
monoamine oxidase inhibitors, e.g., iproniazid, were originally derived from drugs used
to treat tuberculosis (Nestler et al., 2002). Both of these classes of drugs relieve the
symptoms of depression, but have a very poor tolerability and risk profile (Feighner,
1999). The finding that these drugs can relieve depression shed a light on the molecular
mechanism that modulates depressive symptoms in the brain. Over the past 50 years,
depression research has been focused on understanding of how these drugs work and on
finding better drugs with better tolerability and safety (Dubarek and Kucia, 2007). This
led to the development of a number of second-generation antidepressants, which includes
selective serotonin reuptake inhibitors (SSRIs), reversible inhibitors of monoamine
oxidase A (RIMAs; e.g.,moclobemide), selective norepinephrine reuptake inhibitors (e.g.,
reboxetine), dual norepinephrine and serotonin reuptake inhibitors (e.g., milnacipram,
venlafaxin, duloxetine), and some other

drugs with distinct neurochemical actions

(Nelson, 1997; Stahl, 1998). Studies in patients and animal models provide clues to how
brain function is altered by antidepressant treatment (Pacher and Kecskemeti, 2004).
Unfortunately, even the more recently developed antidepressants are still of limited utility
due to their incomplete efficacy and side effects (Blier, 2001). Further, their mechanism
of action remains incompletely understood.
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Notably, inhibition of serotonin and

norepinephrine reuptake enhances the actions of transmitters immediately but
antidepressants exert their behavioral effects only after a period of sustained treatment
(Blier, 2001).

This suggests that adaptation to the increased neurotransmission

contributes to antidepressant efficacy.

1.5 Phosphodiesterase-4
Cyclic nucleotide phosphodiesterase (PDE) enzymes were first discovered by
Thompson and Appleman in a variety of tissues from different species (Thompson and
Appleman, 1971a; Thompson and Appleman, 1971b). To date, eleven families have been
identified according to their substrate specificity, inhibitor sensitivities, and kinetic
properties (Lugnier, 2006). Based on the substrate, the PDE family is divided into three
groups: cAMP-specific PDEs, including PDE4, PDE7, and PDE8; cGMP-specific PDEs,
including PDE5, PDE6, and PDE9; and dual-substrate PDEs, including PDE1, PDE2,
PDE3, PDE10, and PDE11. All the PDE families have the same general structure, which
includes a highly conserved catalytic domain within the central to C-terminal region and
variable, differentially spliced, N-terminal regions responsible for regulating enzyme
activity and intracellular location (Beavo and Brunton, 2002; Houslay and Adams, 2003).
Among PDE families, PDE4 is the most critical enzyme for modulating intracellular
cAMP levels in the brain. PDE4 was first described by Reeves using ion-exchange
chromatography to separate fractions of PDE activity from heart tissue; the fourth peak of
PDE activity was found to be specific for cyclic AMP (Reeves et al., 1987); at the time, it
was termed PDE IV. Further study revealed that PDE4 has high affinity for cAMP but
not cGMP (Km value for cAMP is 1-3 uM) and that is potently inhibited by rolipram
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(Bolger et al., 1996; Nemoz et al., 1997; Francis et al., 2001). To date, four subtypes of
PDE4 have been identified; these are encoded by four genes, PDE4A, B, C, D, which
encode 25 different splice variants. These PDE4 splice variants are divided into three
groups: long form; short form, and super-short form as shown in Figure 1.1 (O'Donnell
and Zhang, 2004; Houslay et al., 2007). Long form PDE4 contains upstream conserved
regions UCR1 and UCR2. UCR1 has a conserved domain which can be phosphorylated
by cAMP-dependent protein kinase (PKA). This modification enhances the activity for
hydrolyzing cAMP (Sette and Conti, 1996; MacKenzie et al., 2002). Short form PDE4
has UCR2 but not UCR1, while the super-short form only has part of UCR2 (Johnston et
al., 2004; Houslay et al., 2007; Chandrasekaran et al., 2008; Lynex et al., 2008). All the
PDE4 enzymes have a highly conserved catalytic domain in the central to C-terminal
region. In addition, PDE4B, C, and D also contain an ERK phosphorylation site in the
catalytic domain, which regulates long, short, and super-short forms differentially
(Houslay et al., 2007).
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Figure 1.1 Structure of PDE4 enzymes. PDE4 has four genes, PDE4A, B, C and D; each
expresses approximately 3-11 alternative spliced variants at N-terminus. According to
their structure, PDE4 are classified as long, short and super-short forms (Zhang, 2009)
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1.6 High and Low Affinity Rolipram Binding States
Based on the binding of the inhibitor rolipram, PDE4 has two different
conformations termed the high-affinity rolipram binding state (HARBS) and the lowaffinity rolipram binding state (LARBS); rolipram exhibits Kd values of approximately 2
nM and 200 nM, respectively, for these conformations (Jacobitz et al., 1996; Souness and
Rao, 1997). The HARBS is present in the brain, while the LARBS is present in both
brain and peripheral tissues (Kaulen et al., 1989; Souness and Rao, 1997; Zhang et al.,
2006). Consistent with their distribution, the HARBS is associated with head twitches,
tremor, hypothermia, and emesis (Schmiechen et al., 1990), while the LARBS is
associated with anti-inflammatory effects (Souness and Rao, 1997).

Chronic

antidepressant treatment induces an increase in the HARBS but not the LARBS in rat
brain (Zhao et al., 2003a).
It has been shown that PDE4 inhibitors, rolipram preferentially binds to the HARBS
while CDP840 has some preference for the LARBS; piclamilast binds with equal, high
affinity to both the HARBS and the LARBS (Zhao et al., 2003a). All three compounds
can penetrate the blood brain barrier after peripheral administration (Zhang et al., 2006).
Jacobitz and coworkers have shown that PDE4 inhibitors bind to both the HARBS and
LARBS at the catalytic site; the HARBS depends on the presence of N-terminal domain
of the protein (Jacobitz et al., 1996).

Overall, all the studies suggest HARBS and

LARBS represent inhibitor binding to the same site but to different conformations,
resulting in different, inhibitor-specific, binding affinities. It is likely that interactions of
PDE4 with other proteins in the brain may stabilize the HARBS (Zhang et al., 2006).
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1.7 PDE and Antidepressant Effects
The cAMP signaling pathway is involved in the therapeutic actions of
antidepressants and the antidepressant-like effects of PDE4 inhibitors (Table 1.2) (D'Sa
and Duman, 2002; Manji et al., 2003). Mice deficient in the PDE4D subtype exhibit
increased cAMP signaling in the brain and an antidepressant-like behavioral phenotype
effect, as evidenced by decreased immobility time in the forced-swim test (Zhang et al.,
2002). Chronic antidepressant treatment increases CREB mRNA and protein levels in
rat hippocampus compared with non-antidepressant, psychotropic drug treatment (Nibuya
et al., 1996). In addition, repeated treatment with rolipram increases CREB activity and
phosphorylation in rat cerebral cortex (Itoh et al., 2004; Monti et al., 2006).

Chronic

antidepressant treatment also increases cAMP signaling at several levels, including upregulation of the stimulatory GTP-binding protein Gs to adenylyl cyclase, activation of
PKA and enhanced expression and function of CREB (Duman and Vaidya, 1998).
Animal studies also suggest that electroconvulsive shock, an effective antidepressant
treatment, also potentiates cAMP signaling, including CREB (cAMP response element
binding protein) and neurotrophic factor BDNF (Nibuya et al., 1996; Frechilla et al.,
1998). Other studies demonstrate that over-expression of CREB in the hippocampus
exerts antidepressant-like effects in preclinical models (Chen et al., 2001). Further,
chronic antidepressant treatment increases the expression of PDE4 in the frontal cortex
and nucleus accumbens via a compensatory mechanism (Takahashi et al., 1999).
Overall, these findings suggest that induction of CREB function via the cAMP-signaling
cascade by PDE4 inhibitors plays a pivotal role in their antidepressant actions.
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Neurogenesis occurs in the adult brain of different species, including humans, rats,
mice and monkeys; it is regulated by a variety of neurochemical, endocrine, and
environmental factors (van Praag et al., 2005). Exercise and enriched environmental
conditions enhance neurogenesis; aging and stress decrease it (Cameron and McKay,
1999).

Recent studies have suggested that depression is associated with decreased

volume and function of the hippocampus that may result from reduced neurogenesis;
antidepressants increase hippocampal function by increasing neurogenesis via the
cAMP/CREB signaling pathway as described in figure 1.2 (Takahashi et al., 1998;
Nakagawa et al., 2002). Increased neurogenesis is associated with antidepressant-like
effects on behavior and enhanced learning and memory (Finkbeiner, 2000; Santarelli et
al., 2003).
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Table 1.2 PDE4 inhibitors
Rolipram

Piclamilast

CP840

MF

C16H21NO3

C18H18Cl2N2O3

C25H27NO2

IUPAC

4-3-cyclopentyloxy-4methoxyphenylpyrrolidin-2one

3-cyclopentyloxy-N-3,5dichloropyridin-4-yl-4methoxybenzamide

4-[2R-2-3-cyclopentyloxy-4methoxyphenyl-2phenylethyl]pyridine

Structure
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Figure 1.2. Modulation of the cAMP/CREB signaling pathway by PDE4 inhibitors. PDE4
inhibitors, e.g., rolipram, increase cAMP levels by inhibiting PDE4 activity, thus
increasing phosphorylation of CREB which initiates transcription of a number of genes.
P, phosphate group; CREB, cAMP response element binding protein; DISC1, disrupted
in schizophrenia 1.
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1.8 Genetic Linkage Studies of Disrupted in Schizophrenia 1 (DISC1)
Major mental diseases consist of schizophrenia, schizoaffective disorder, bipolar
disorder and major depression. The incidences of these diseases have increased during
the past years and are very devastating in humans (Devon et al., 2001). These diseases
share some common symptoms and risk factors and are induced by combination of both
genetic and environmental effects (Semple et al., 2001). Current studies have pointed out
that environmental factors play an important role in neuronal development which
contributes to the pathogenesis of mental diseases (Badner and Gershon, 2002).
Mutations in “Disrupted in Schizophrenia 1” (DISC1) have been shown to be a risk factor
for mental illness, including schizophrenia, bipolar disorder, and depression (Hodgkinson
et al., 2004; Millar et al., 2004).
DISC1 was first reported in a Scottish family. In this family, 34 of the 77 people
carried a translocation between chromosome (t1: 11) (q43, q21) by genetic analysis, and
16 of 34 carriers were diagnosed with psychiatric illness compared with 5 out of 43
members without translocation (St Clair et al., 1990). This provides strong evidences for
the link between DISC1 and psychiatric illness (Blackwood et al., 2001). Studies of a
Finnish population also show a strong linkage between schizophrenia or schizoaffective
disorder and the disruption of DISC1 gene (Ekelund et al., 2001). Furthermore, genetic
analysis of populations in Taiwan, Scotland, Iceland, and Britain also suggest an
association of DISC1 gene with psychiatric illness (Liu et al., 2006).
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1.9 DISC1 Expression in Developing Brain and Adult Brain
Studies indicate that DISC1 is distributed in many human tissues such as heart, brain,
and placenta at both RNA and protein levels (Millar et al., 2000a). Studies of the
postmortem human brain show that DISC1 expression is expressed widely (Lipska et al.,
2006). Studies of rodents and primates including African Green Monkeys and Rhesus
Monkeys by western blotting and immunohistochemistry also show similar expression
patterns of DISC1 as that observed in humans (Austin et al., 2003; Bord et al., 2006).
DISC1 plays an important role in early brain development and adult brain function. In
the developing mouse brain, DISC1 is distributed throughout the brain, particularly in the
bed nucleus of stria terminals, neocortex, limbic system, and thalamic nuclei, and
maintained in the hippocampus throughout development (Austin et al., 2004).

By

immunohistochemistry and western blotting, DISC1 is detected at every stage from
embryonic day 10 to 6 months old, with two peaks of expression at E13.5 and P35
(Schurov et al., 2004). These time points are important stages for the mouse brain
development, especially neurogenesis in the hippocampus. The pattern and timing of the
expression indicates a role of DISC1 in the brain development and maturation (Miyoshi
et al., 2003; Ozeki et al., 2003; Austin et al., 2004; Schurov et al., 2004)

1.10 DISC1 Protein Interaction
Examination of DISC1 by immunocytochemistry reveals a cytoplasmic location and
overlap with F-actin, a-tubulin, MAP2, and gelsolin, indicating that DISC1 interacts with
many cytoskeletal proteins (Miyoshi et al., 2003; Brandon et al., 2004; Kamiya et al.,
2005). DISC1 localizes to the centrosome via interaction with LIS/NDEL, modulating
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local microtubule dynamics (Morris et al., 2003).

Over-expression of C-terminal

truncated DISC1 disrupts assembly of LIS1, NDEL, dynein, dynactin, as well as ytubulin and pericentrin B; this mutation of DISC1 also disrupts the organization of
microtubules (Kamiya et al., 2005). In addition, kinesin-1 heavy chain KIF5B and 14-33  are identified by mass spectrometry as interacting with DISC1. Further studies
demonstrate that 14-3-3 , LIS1 and NDEL1 are necessary for the axonal growth, and this
function only exists in the presence of DISC1 and kinesin (Taya et al., 2007). The 14-3-3
gene is decreased in patients with schizophrenia and upregulated in the prefrontal cortex
of the monkey by the psychiatric treatment with haloperidol and fluoxetine, which are
used to treat schizophrenia and depression, respectively (Middleton et al., 2005; Cecconi
et al., 2007). Affinity chromatography has shown that growth factor receptor-bound
protein Grb2 also interacts with DISC1 (Shinoda et al., 2007). Studies using RNA
interference demonstrate that Grb modulates microtubules assembly and facilitates axon
elongation via a DISC1-dependent process (Shinoda et al., 2007). Fasciculation and
Elongation Factor Zeta (FEZ1) also has been shown to interacts with DISC1 in rat brain
(Honda et al., 2004; Ikuta et al., 2007). Reduced expression of FEZ1 compromises axon
growth, while over-expression of FEZ1 increases DISC1 binding and neurite length
(Miyoshi et al., 2003). Yeast two-hybrid studies demonstrate that DISC1 interacts with a
number of other proteins, including activating transcription factor 4 (ATF4) (Morris et
al., 2003; Pletnikov et al., 2007), microtubule-associated protein 1A (MAP1A) (Halpain
and Dehmelt, 2006), TNF receptor-associated factor 3 interacting protein 1
(TRAF3IP/MIP-T3 ) (Halpain and Dehmelt, 2006), and DISC1-Binding Zinc-finger
protein (DBZ) (Hattori et al., 2007). Compromised binding of these proteins impairs
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cortical development and neurite outgrowth. Taken together, these studies show that
DISC1 is involved in the processes that are essential for brain development and that
dysfunctions in its function may contribute to the pathogenesis of mental illness (Chubb
et al., 2008).
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Figure 1.3 Interaction between DISC1 and long form PDE4B. Long form PDE4B contain
regulatory domain including UCR1 and UCR2, catalytic domain, and amino-terminal and
carboxy-terminal regions. The enzyme can be activated by phosphorylation by PKA on
UCR1 and inhibited by ERK phosphorylation of the catalytic domain. DISC1 binds to the
UCR2 domain of PDE4B, as well as other PDE4 subtypes, and may induce
conformational changes in DISC1 or PDE4B (Mackie et al., 2007).
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1.11 DISC1 and Psychiatric Illness
To date, there are only a few studies of DISC1 expression in patients with major
mental illness. It has been reported that there are no differences of full length of DISC1
in the postmortem brain samples between schizophrenia and controls, and antipsychotic
treatment does not alter its expression (Lika et al., 2006). Two studies of DISC1 have
been performed in the lymphoblastoid cell lines from patients with psychiatric illness. In
cell lines from patients with t(1:11), the expression of DISC1 mRNA and protein are
decreased compared with controls (Millar et al., 2005). In cell lines from patients with
bipolar disorder, the mRNA of DISC1 also is decreased compared with normal family
members (Maeda et al., 2006). In addition, the decreased expression of DISC1 mRNA is
also correlated with the manic symptoms in bipolar patients (Maeda et al., 2006). Further
studies reveal that antipsychotic treatment in mice up-regulates the DISC1 expression in
both the frontal cortex and the hippocampus (Chiba et al., 2006). Though the data on
DISC1 in patients with psychiatric illness are limited and controversial due to the
differences in samples and method of preparation, extensive studies of DISC1
demonstrate that as a hub protein, DISC1 links a variety of signaling pathways, including
the cAMP signaling, kinesin-mediated transportation, neurite growth and elongation
(Mackie et al., 2007). Meanwhile, it forms complexes with considerable scaffolding
proteins. Therefore, compromised DISC1 function could enhance the risk of developing
mental major diseases (Roberts, 2007).
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Chapter 2
Effects of repeated treatment with phosphodiesterase-4
inhibitors on cyclic AMP signaling, hippocampal neurogenesis,
and behavior in the forced-swim test
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Abstract
The effect of acute and chronic treatment with the phosphodiesterase-4 (PDE4)
inhibitors rolipram, piclamilast, and CDP840, which differ in their interactions with highand low-affinity binding conformers, were determined on cyclic AMP signaling,
hippocampal neurogenesis, and immobility in the forced-swim test in rats.

Acute

treatment with rolipram (3 mg/kg), piclamilast (1 mg/kg), or CDP840 (30 mg/kg) induced
transient increases in cyclic AMP and phosphorylation of cyclic AMP response element
binding protein (pCREB) in rat hippocampus and prefrontal cortex. Chronic treatment
with rolipram (1, 3 mg/kg), piclamilast (0.3, 1 mg/kg), or CDP840 (10, 30 mg/kg) also
increased cyclic AMP and pCREB in hippocampus and prefrontal cortex. In addition,
chronic treatment with the PDE4 inhibitors increased proliferation and survival of
neurons in the hippocampus and, simultaneously, produced antidepressant-like effects on
behavior, as evidenced by decreased immobility in the forced-swim test. Compared with
rolipram and piclamilast, CDP840 exerted lesser effects on neural and behavioral
measures, likely due to its weak interaction with the high-affinity binding conformer of
PDE4.

Overall, the PDE4 inhibitors rolipram, piclamilast, and CDP840 exert their

antidepressant effects via activation of cyclic AMP/pCREB signaling cascade and
increase in hippocampal neurogenesis; this appears to involve inhibitor interaction with
the high-affinity binding conformer.
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Introduction
Phosphodiesterase-4 (PDE4) plays a critical role in modulating cyclic AMP
signaling and is involved in many aspects of cell function (Conti et al., 2003; Houslay
and Adams, 2003; O'Donnell and Zhang, 2004). Altered cyclic AMP signaling has been
suggested to contribute to the pathophysiology of neuropsychiatric illnesses such as
major depression, schizophrenia, and dementia (Tanis and Duman, 2007). Consistent
with this idea, it has been found that PDE4 inhibitors such as rolipram, which increase
cyclic AMP signaling, exert antidepressant- and antipsychotic-like effects, as well as
memory-enhancing effects, on behavior (O'Donnell and Zhang, 2004; Blokland et al.,
2006; Siuciak, 2008).
Antidepressant-like effects of PDE4 inhibitors have been demonstrated using a
number of preclinical models.

Early work demonstrated an antidepressant-like

behavioral profile for rolipram, including reversal of the effects of reserpine and
potentiation of yohimbine toxicity (Wachtel and Loschmann, 1986; Wachtel and
Schneider, 1986). Rolipram and other PDE4 inhibitors also reduce response rate and
increase reinforcement rate of rats under a differential-reinforcement-of-low-rate
schedule of reinforcement (O'Donnell, 1993); such an effect is indicative of an
antidepressant action (O'Donnell et al., 2005). PDE4 inhibitors are active in preclinical
antidepressant screens such as the forced-swim and tail-suspension tests (O'Donnell and
Zhang, 2004). To the extent they have been examined, the antidepressant-like behavioral
effects of PDE4 inhibitors persist with repeated treatment (Li et al., 2009). Finally,
clinical studies have demonstrated antidepressant effects of rolipram; however, issues
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related to side effects and toxicity have limited its clinical utility (Zeller et al., 1984;
Fleischhacker et al., 1992).
There are four PDE4 subtypes, PDE4A, B, C, and D, which undergo differential
splicing resulting in 25 PDE4 isozymes. Through the examination of the behavioral
phenotypes of mice deficient in PDE4 subtypes, some understanding of their relative
roles has begun to emerge. Mice deficient in PDE4D exhibit an antidepressant-like
behavioral phenotype, as evidenced by reduced immobility in the forced-swim and tailsuspension tests, and altered hippocampal LTP and memory (Zhang et al., 2002; Rutten
et al., 2008). PDE4B-deficient mice exhibit an anxiogenic behavioral profile, as well as
reduced prepulse inhibition of an acoustic startle response, consistent with an
antipsychotic-like effect (Siuciak et al., 2007; Zhang et al., 2007). The behavioral effects
of rolipram, which is not subtype-selective, are somewhat diminished in both PDE4Dand PDE4B-deficient mice (Zhang et al., 2002). There are no published data as yet on
the behavioral consequences of PDE4A deficiency and PDE4C is not expressed in the
brain.
While rolipram does not inhibit the PDE4 subtypes with different potencies, its
interaction with the enzyme is complex. Using an equilibrium dissociation assay, it was
found that [3H]-rolipram binds to PDE4 with two distinct affinities, which have been
termed the high- and low-affinity rolipram binding states (HARBS, LARBS) (Jacobitz et
al., 1996). This has been confirmed using [3H]-piclamilast, a PDE4 inhibitor which binds
with equal, high affinity to the HARBS and LARBS; interestingly, while LARBS is
found both in the brain and peripheral tissues, the HARBS is only fou nd in the brain
(Zhao et al., 2003a). Consistent with this, it has been observed that the HARBS and
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LARBS mediate distinct pharmacological effects (Saccomano et al., 1991; Barnette et al.,
1996; Zhao et al., 2003a).
It appears that PDE4 is involved in signaling pathways affected by antidepressant
drugs.

Repeated treatment of mice with antidepressants or rolipram increases the

expression of PDE4 in cerebral cortex and hippocampus, with the PDE4D subtype being
affected the most consistently (Dlaboga et al., 2006). There appears to be some species
dependence since similar treatment of rats has pronounced effects on PDE4A expression
(Takahashi et al., 1999; Ye et al., 2000). It is likely that increased PDE4 expression is a
compensatory change in response to increased cyclic AMP signaling that results from
antidepressant treatment; prior work demonstrated such regulation of PDE4 in neurons
(D'Sa et al., 2002; Hajjhussein et al., 2007).

Repeated treatment of rats with

antidepressant drugs also increases the HARBS, but not the LARBS in cerebral cortex
and hippocampus (Zhao et al., 2003a). Consistent with this finding, comparison of the
acute behavioral effects of rolipram, piclamilast, and CDP840, PDE4 inhibitors that differ
in their interactions with the HARBS and LARBS (Zhao et al., 2003b), suggests a
predominant role for the HARBS in mediating antidepressant-like effects on behaviors
(Zhang et al., 2006).
The effects of antidepressants on behavior depend to some degree on increased
neurogenesis in the dentate gyrus of the hippocampus. Inhibition of neurogenesis blocks
some, but not all, effects of antidepressants on behavior (Santarelli et al., 2003; Holick et
al., 2008). Similarly, repeated treatment of mice with rolipram, which increases cyclic
AMP signaling, as evidenced by an increase in phosphorylation of cyclic AMP response
element binding protein (pCREB), also increases hippocampal neurogenesis; inhibition of
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rolipram-induced neurogenesis reduces antidepressant-like effects on behavior (Li et al.,
2009).

The relationship among the ability of PDE4 inhibitors to interact with the

HARBS and LARBS to alter cyclic AMP signaling, increase neurogenesis, and produce
antidepressant-like effects on behavior has not been well characterized. Comparison of
the effects of rolipram, piclamilast, and CDP840 on these measures should provide some
insight, since acutely they affect behavior differently, even though all are potent PDE4
inhibitors (Zhang et al., 2006). In addition, such a comparison will show the extent to
which the HARBS and the LARBS contribute to altered cyclic AMP signaling in the
brain and increased hippocampal neurogenesis. The present study compared the effects
of repeated treatment with these three PDE4 inhibitors on behavior in the forced-swim
test, hippocampal neurogenesis measured using flow cytometry, and cyclic AMP
signaling assessed by measurement of cyclic AMP and pCREB following euthanasia by
focused microwave fixation to prevent post-mortem changes. The results suggest the
importance of the HARBS in these measures and a close association among increased
cyclic AMP signaling, neurogenesis, and antidepressant-like effects on behavior.
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Materials and Methods
Animals
Male Sprague-Dawley rats (Harlan, Indianapolis, IN), weighing 200-250 g, were
housed individually in clear plastic cages in a room that was maintained at 22C with a
12-h on/12-h off light cycle lights on at 7:00 a.m. Food and water were freely available.
All experiments were carried out according to the “NIH Guide for the Care and Use of
Laboratory Animals,” revised 1996, and were approved by the Institutional Animal Care
and Use Committee of West Virginia University.

Drug Treatments
Rolipram was purchased from Sigma Aldrich (ST. Louis. MO); piclamilast and
CDP840 were provided by Memory Pharmaceuticals (Montvale, NJ). To assess the
effects of repeated treatment, rats were injected i.p. with 1 or 3 mg/kg rolipram, 0.3 or 1
mg/kg piclamilast, 10 or 30 mg/kg CDP840, or the 10% DMSO/saline vehicle once daily
for 16 consecutive days. Two hours after the last treatment, separate groups of rats were
subjected to the five-minute forced-swim test, used for measurement of cyclic AMP and
pCREB, or started on the BrdU treatment regimen for assessment of neurogenesis.
To assess the effects of acute treatment on forced-swim behavior, 0.3, 1, or 3 mg/kg
rolipram, 0.3, 1 or 3 mg/kg piclamilast, 3, 10 or 30 mg/kg CDP840, or vehicle was
administered to separate groups of rats and the time of immobility assessed either 0.5 or 2
hrs post-treatment.

To assess the effects of acute treatment on the neurochemical

measures, 3 mg/kg rolipram, 1 mg/kg piclamilast, 30 mg/kg CDP840, or vehicle was
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administered and rats were killed by focused microwave fixation 0.5, 1, 2, 3, or 4 hrs
later.

Measurement of Cyclic AMP and pCREB
To prevent post-mortem changes in cyclic AMP and pCREB, rats were killed by
focused microwave fixation (O'Callaghan and Sriram, 2004) (Muromachi Microwave
Applicator, TMW-4012C, 10kW output; Stoelting, Kiel, WI).

For cyclic AMP

measurement, hippocampus and prefrontal cortex were homogenized in ice-cold 0.1N
hydrochloric acid and centrifuged at 13,000 g for 50 min at 4ºC. Cyclic AMP in the
supernatant was measured by ELISA (Assay Designs, Ann Arbor, MI) and normalized to
protein content(Smith et al., 1985) (Bio-Rad Laboratories, Hercules, CA).
For CREB and pCREB measurement, hippocampus and prefrontal cortex were
homogenized in ice-cold RIPA lysis buffer (Upstate, Temecula, CA) and centrifuged at
10,000 g for 30 min at 4C. Solubilized samples were mixed with equal volumes of
Laemmli sample buffer and heated to 100C for 2 minutes. Equal amounts of sample
protein were loaded onto gels for SDS-PAGE. Following separation by electrophoresis,
proteins in the gels were transferred to nitrocellulose membranes, which were incubated
overnight at 4C with primary antibodies against CREB or pCREB (i.e., phosphorylated
at serine-133, Millipore Billerica, MA) and then with Alexa Fluor 680-conjugated
secondary antibody for 30 min at room temperature (Invitrogen, Carlsbad, CA). An
Odyssey Infrared Imaging System (LI-COR Bioscience, Lincoln, NE) was used for
quantifying fluorescence.

Treatment-induced changes in CREB and pCREB were

assessed within individual gels/immunoblots by densitometry.
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Measurement of Neurogenesis by Flow Cytometry
To evaluate the effects of repeated treatment with PDE4 inhibitors on hippocampal
cell proliferation, rats were administered 100 mg/kg BrdU, i.p.,two hours after the last
injection of PDE4 inhibitors in order to label dividing cells; rats were killed and BrdU
labeling quantified 24 hours later. To evaluate effects on hippocampal cell survival, rats
were administered 100 mg/kg BrdU, i.p., 4 times at 2 hours intervals one day after the
last injection of the PDE4 inhibitors; rats were killed and BrdU labeling quantified five
weeks later.
Neurogenesis in the hippocampus was measured by flow cytometry as described
previously (Bilsland et al., 2006; Balu et al., 2009). Rats were killed by decapitation and
hippocampi were dissected, placed in 1.5ml Eppendorf tubes containing Dulbecco's
phosphate-buffered saline (D-PBS; Invitrogen, Carlsbad, CA) and finely minced. An
enzymatic cocktail comprised of digestive solution (papain 2.5 U/ml, dispase 1 U/ml, and
DNase I 250 U/ml) was added to each tube, which was then incubated at 37C for 30
min. The samples were triturated and washed twice with DMEM/10% fetal bovine serum
and then once with D-PBS.
The samples were centrifuged at 500 x g for 5 min and stained using a FITC BrdU
Flow Kit (BD Bioscience, San Jose, CA). Precipitated cells were suspended in BD
Cytofix/Cytoperm buffer and incubated for 30 min on ice. After washing twice with 1 ml
of BD perm wash buffer, the cells were further permeabilized by resuspension with
Cytoperm Plus buffer on ice for 10 min. After washing, the cells were refixed in CytofixCytoperm buffer for 5 min and then incubated with DNase for 1 hr at 37C. After
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washing with BD buffer, the cells were labeled with 50µl of FITC-conjugated antiBrdU1:50 for 20 min. After another wash, cells were labeled with 20µl of 7-AAD at
room temperature. The BrdU-positive cells were counted by FACS Calibur and analyzed
using Cellquest Prosoftware (Becton Dickinson, BD Bioscience, San Jose, CA).

Forced-Swim Test
The forced-swim test was performed as described previously (Zhang et al., 2006);
this consisted of a 15-min pre-test and a 5-min test 24 hr later.

Rats were place

individually in a Plexiglas cylinder 45 cm high × 20 cm diameter filled with water 2223°C to a depth of 30 cm. During the 5-min test, the time of immobility, defined as
floating in an upright position with the only movement being that necessary for an animal
to keep its head above water, was recorded.

Data Analysis and Statistics
Data were analyzed by one-way analysis of variance followed by Dunnett’s test.
Data are expressed as means  SEM. A p value of < 0.05 was considered statistically
significant.
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Results
Effects of repeated treatment with rolipram, piclamilast, and CDP840 on cyclic
AMP and pCREB.
Repeated treatment for 16 days with the PDE4 inhibitors increased cyclic AMP in
hippocampus and prefrontal cortex (Fig.2.1). Significant increases were observed only at
the higher doses of rolipram (3 mg/kg), piclamilast (1 mg/kg), or CDP840 (30 mg/kg)
that were tested. At the higher doses, rolipram, piclamilast, and CDP840 increased cAMP
by 204%, 250%, and 145%, respectively, in hippocampus and by 168%, 189%, and
112%, respectively, in prefrontal cortex.
Parallel effects of repeated treatment with the PDE4 inhibitors on pCREB were
observed (Fig.2.2). However, both the lower and higher doses tested were effective:
doses of 1, 3 mg/kg rolipram increased pCREB in hippocampus by 59% and 75%,
respectively;0.3, 1 mg/kg piclamilast by 58% and 82%, respectively; and 10, 30 mg/kg
CDP840 by 36% and 55%, respectively. Doses of 1, 3 mg/kg rolipram increased pCREB
in prefrontal cortex by 61% and 70%, respectively, 0.3, 1 mg/kg piclamilast by 59% and
85% respectively, and 10, 30 mg/kg CDP840 by 32% and 60%, respectively. None of
these treatments affected CREB expression (data not shown).

Effects of repeated treatment with rolipram, piclamilast, and CDP840 on
hippocampal neurogenesis.
The proliferation and survival of newborn cells in rat hippocampus were measured
after repeated treatment with rolipram, piclamilast, or CDP840 (Fig.2.3). Sixteen-day
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treatment with 1, 3 mg/kg rolipram or 0.3, 1 mg/kg piclamilast increased both cell
proliferation and survival in the hippocampal samples, but the effects on survival were
only significant at the higher doses.

Repeated treatment with 30 mg/kg CDP840

increased cell proliferation but not survival.

Effects of repeated treatment with rolipram, piclamilast, and CDP840 on forcedswim behavior.
Repeated treatment with PDE4 inhibitors for sixteen days produced antidepressantlike effects on the behavior of rats in the forced-swim test in a dose-dependent manner
(Fig.2.4). Two hours following the last injection, 1 and 3 mg/kg rolipram, 0.3 and 1
mg/kg piclamilast, and 10 and 30 mg/kg CDP840reduced the time of immobility. At the
doses tested, rolipram and piclamilast tended to produce greater reductions in immobility
than did CDP840.

Effects of acute treatment with rolipram, piclamilast, and CDP840 on immobility in
the forced-swim test, cyclic AMP, and pCREB.
Acute treatment with 3 mg/kg rolipram, 1 mg/kg piclamilast, or 30 mg/kg CDP840
increased cyclic AMP in prefrontal cortex and hippocampus in a time-dependent manner
(Table.2.1). The peak effects of the inhibitors were observed 2 hours post-treatment.
Similar effects of the PDE4 inhibitors were observed on pCREB in prefrontal cortex and
hippocampus (Table.2.1), with a peak effect also 2 hours post-treatment.
Immobility in the forced-swim test was recorded 30 min or 2 hr after administration
of the PDE4 inhibitors. Doses of 0.3 mg/kg rolipram, 0.3 mg/kg piclamilast, and 3 mg/kg
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CDP840 decreased immobility in the forced-swim test at 30 min after acute treatment,
but not 2 hours post-treatment (Table.2.2). Acute treatment with higher doses of the
PDE4 inhibitors did not affect immobility in the forced-swim test at either time point.
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Discussion
Repeated treatment with all three PDE4 inhibitors enhanced cyclic AMP signaling in
hippocampus and prefrontal cortex, as evidenced by increased cAMP and pCREB. These
inhibitors also increased hippocampal neurogenesis and produced antidepressant-like
effects on forced-swim behavior. However, rolipram and piclamilast, which bind to the
HARBS with high affinity, were more potent at increasing cAMP/pCREB signaling and
hippocampal neurogenesis than CDP840, which has lower affinity for the HARBS (Zhao
et al., 2003b). Similarly, rolipram and piclamilast were more potent at decreasing the
time of immobility in the forced-swim test.
The HARBS and LABRS were first described in a study that showed that [3H]rolipram binds to recombinant PDE4A with two distinct affinity states with a 500-fold
difference in Ki values (Jacobitz et al., 1996). The HARBS is only observed in the
central nervous system, while the LABRS is present in both the brain and peripheral
tissues (Zhao et al., 2003b). While, rolipram exhibits different affinities to the HARBS
and LARBS, piclamilast exhibits equal high affinity for both (Zhao et al., 2003b), and
CDP840, by contrast, interacts with relatively low, but similar affinity with both states
(Zhao et al., 2003b). The present findings suggest that inhibitor interactions with the
HARBS are important for mediating neurochemical and behavioral effects of rolipram,
piclamilast, and CDP840.Repeated treatment with rolipram or piclamilast increased
cAMP signaling and neurogenesis and produced antidepressant-like behavioral effects at
doses below those of CDP840 that could effective.
Previously, it has been found that repeated treatment with the antidepressant drugs
desipramine and fluoxetine increases the HARBS in brain, measured either by [ 3H]-
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rolipram or [3H]-piclamilast binding (Zhao et al., 2003a). By contrast, such treatment
does not alter the LARBS in brain. The effects of fluoxetine and desipramine on the
HARBS in the brain are prevented when noradrenergic or serotonergic neurons are
lesioned with 6-hydroxydopamine (6-OHDA) or 5, 7-dihydroxytryptamine (5,7-DHT),
respectively (Zhao et al., 2003a).

This suggests that the neurochemical pathways

involved in the mediation of antidepressant activity can influence PDE4 expression and
activity. In rats trained to discriminate rolipram from vehicle, only PDE4 inhibitors
which have a high affinity for the HARBS generalize to rolipram (Zhang et al., 2006).
Similarly, when the effects of acute treatment with PDE4 inhibitors on forced-swim
behavior are examined, a potency order of piclamilast > rolipram > CDP840 is observed
(Zhang et al., 2006); this is consistent with their relative affinities for the HARBS (Zhao
et al., 2003a).
Previous studies have shown that hippocampal neurogenesis plays an important role
in some effects of antidepressants that depend on repeated treatment (Santarelli et al.,
2003). In addition, the time-course of the change in neurogenesis in hippocampus is
consistent with the delayed onset of antidepressant efficacy (Sahay and Hen, 2007).
Present studies show that repeated treatment with rolipram and piclamilast also increased
hippocampal neurogenesis. Interestingly, repeated treatment with CDP840 at 10 or 30
mg/kg decreased immobility in forced-swim test, indicating an antidepressant-like effect,
but did not increase hippocampal proliferation. Other studies also have shown that some
antidepressant-like behavioral effects do not depend completely on neurogenesis (Airan
et al., 2007; David et al., 2007; Wang et al., 2008). This suggests that neurogenesis
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might not be the only mechanism underlying PDE4 inhibitor-mediated antidepressantlike effects on behavior.
When rats were treated acutely with the PDE4 inhibitors rolipram, piclamilast, or
CDP840, there was dissociation between neurochemical and behavioral effects. The
time- course revealed peak effects at 2 hrs post-acute treatment; by contrast, PDE4
inhibitors decreased immobility in the forced-swim test 30 min post-treatment, but not at
2 hrs post-treatment. In addition, in contrast to the monotonic dose-response curve for
the effects of repeated treatment, acute treatment with higher doses of the PDE4
inhibitors no longer decreased immobility. It is possible that sedative effects of higher
doses may confound the results in the forced-swim test following acute treatment, but
that some tolerance may develop with repeated treatment.
Previous studies have shown that long-term antidepressant treatment increases cyclic
AMP as well as phosphorylation of CREB in specific brain regions. The activated cyclic
AMP/pCREB signaling cascade induces increased expression of brain-derived
neurotrophic factor (BDNF) in the hippocampus and cerebral cortex (Duman et al., 1997).
In addition, chronic administration of either a 5-HT or norepinephrine selective reuptake
inhibitor, enhances neurogenesis in adult rodent hippocampus via up-regulation of
cAMP/pCREB signaling (Duman et al., 2001).

Interestingly, cell proliferation is

decreased in transgenic mice that express a dominant negative mutant of CREB in the
hippocampus (Nakagawa et al., 2002).

Furthermore, electroconvulsive shock, an

effective antidepressant therapy, also enhances phosphorylation of CREB in rat
hippocampus (Jeon et al., 1997).

These studies demonstrate that, like proven

antidepressants, PDE4 inhibitors produce persistent, enhanced cAMP signaling, altering
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transcription of neurotrophic factors, increasing hippocampal neurogenesis, and
contributing to antidepressant-like effects on behavior.
In a summary, it was found that repeated treatment with PDE4 inhibitors
increasedcyclic AMP/pCREB signaling and hippocampal neurogenesis and also produced
antidepressant-like effects on behavior. Comparison of the neurochemical and behavioral
effects of rolipram, piclamilast, and CDP840 suggests that interaction with HARBS, in
contrast to the LARBS, mediates these effects. Improved understanding of molecular
mechanisms that contribute to the presence of two PDE4 affinity states in the brain may
suggest targets for antidepressant drug discovery; potential candidate includes scaffolding
proteins (McCahill et al., 2005; Millar et al., 2005) and unique conserved regions of the
N-terminal of PDE4 (Burgin et al., 2010).
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Figure Legends

Fig. 2.1. Effects of repeated treatment with rolipram, piclamilast, or CDP840 on cyclic
AMPin rat brain. Treatment for 16 days with rolipram, piclamilast, or CDP840 increased
cyclic AMP in hippocampus and prefrontal cortex. Bars represent means ± SEM, n=3-4
per group. **P<0.01; *P<0.05 vs. corresponding control.

Fig. 2.2. Effects of repeated treatment with rolipram, piclamilast, or CDP840 on pCREB
in rat brain. Treatment for 16 days with rolipram, piclamilast, or CDP840 increased
pCREB in hippocampus and prefrontal cortex; none of the treatments affected CREB.
Bars represent means ± SEM, n=3-4 per group. **P<0.01vs. corresponding control.

Fig. 2.3. Effects of repeated treatment with rolipram, piclamilast, or CDP840 on cell
proliferation and survival in rat hippocampus. Treatment for 16 days with rolipram or
piclamilast increased cell proliferation (A) and survival (B). CDP84030mg/kgtreatment
increased proliferation (A) but not survival (B). Bars represent means ± SEM, n=3-4 per
group. **P<0.01; *P<0.05 vs. corresponding control.

Fig. 2.4. Effects of repeated treatment with rolipram, piclamilast, or CDP840 on
immobility of rats in the forced-swim test.

Treatment for 16 days with rolipram,

piclamilast, or CDP840 decreased immobility time in a dose-dependent manner. Bars
represent means ± SEM, n=4-5 per group. **P<0.01; *P<0.05 vs. corresponding control.
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Table 2.1. Effects of acute treatment with PDE4 inhibitors on cyclic AMP and
pCREB in hippocampus and prefrontal cortex

hours post-treatment
Control

0.5

1

2

3

4

Rolipram (3mg/kg)

Hippocampus

cyclic AMP

17.5  1.9a

24.9  3.5

47.5  4.5*

68.9  5.7**

47.8  3.0*

23.5  5.0

pCREBb

100a

101.8  5.0

131.8  8.2

182.5  11.0*

126.3  8.1

116  7.8

Prefrontal

cortex

18.7  2.7

24.8  3.0

44.7  5.1*

61.0  7.3**

40.3  4.2*

25.4  6.0

100

103  5.9

123.5  7.5

160.8 10.5*

127.5  10.9

116  7.8

cyclic AMP
pCREB
Piclamilast (1mg/kg)

Hippocampus

cyclic AMP

21  1.1

38.5  4.7

58.8 6.1**

73  7.9**

49.5  5.5**

38.5  3.9

pCREB

100

102.3  7.4

117.3  11.6

157.3  14.8*

133.0  8.6

109.8  7.0

Prefrontal

cortex

18.7  2.7

38.8  4.9

73.3  4.5**

89.3  6.1**

52.3  11.5*

36.0  7.1

100

98.5  9.2

129.8 9.8

156  10.0*

124.3 5.1

101.3 6.8

cyclic AMP
pCREB
CDP840 (30mg/kg)

Hippocampus

cyclic AMP

22.0  3.9

30.8  3.0

42.7  6.6*

51.5  4.1**

42.6  5.6*

26.1  2.9

pCREB

100

111.7  2.3

135.7  16.6

141.3  9.3*

125.3  7.2

102.3  3.6

Prefrontal

cortex

23.8 3.7

29.2  5.6

32.5  2.1

52.2  4.1**

32.3  4.1

27.8  4.0

100

111.7  2.4

117.0  8.2

136.3  12.1*

125.3  7.0

102.3  3.5

cyclic AMP
pCREB

a

Values shown are means  SE expressed as pmol/mg protein cyclic AMP or percentage of control pCREB; n=6 per
group.

b

None of the treatments affected CREB.

**P<0.01; *P<0.05 vs. corresponding control.
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Table 2.2. Effects of acute treatment with PDE4 inhibitors on immobility in the
forced-swim test
Immobility (sec)
0.5 hr b

2 hr

154  10.2a

138  14.2

0.3

84  12.1*

144  7.4

1

174  9.2

122  7.0

3

201  8.6

127  10.9

0.3

58  6.24**

132  5.9

1

117  25.5

122  5.8

3

129  25.4

123  9.3

3

91  6.5*

141  10.6

10

122  19.0

126  12.5

30

125  15.0

123  6.1

Vehicle
Rolipram (mg/kg)

Piclamilast (mg/kg)

CDP840 (mg/kg)

Values shown are means  SE for times of immobility of separate groups of rats tested in the forced-swim test; n=6

a

per group.
b

Rats were treated with PDE4 inhibitors and tested in forced-swim test 0.5 or 2 hr post-treatment.
**P<0.01; *P<0.05 vs. corresponding control.
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Figure 2.1
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Figure2.2
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Figure 2.4
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Chapter 3
Effect of DISC1 mutation on cAMP/pCREB signaling and
PDE4 isoforms
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Abstract
Disrupted in schizophrenia 1 (DISC1) is among the most reproducible genetic risk
factors that have been identified for psychiatric disorders. Phosphodiesterase-4 (PDE4),
notably the PDE4B subtype, which interacts strongly with DISC1, is another identified
risk factor. The purpose of this study is to investigate how alterations in DISC1 affect
PDE4 using mutant mice expressing mutated DISC1. Using a mouse strain carrying an
endogenous DISC1 construct engineered to model the disease-associated chromosomal
translocation found in humans, PDE4 expression and activity were examined. In DISC1
mutant mice, it was found that PDE4 activity was reduced and cAMP/pCREB singling
was increased in the hippocampus, prefrontal cortex, and striatum. Examination of PDE4
subtypes using SDS-PAGE/immunoblotting showed reduced expression of PDE4B1,
PDE4B3, and PDE4B4 in these three brain regions. PDE4D expression was decreased
only in the hippocampus and PDE4A was not unchanged. Interestingly, the high affinity
rolipram binding state, a conformer of PDE4, found only in brain, also was decreased in
DISC1 mutant mice. These data suggest that DISC1 modulates PDE4 expression and
function, notably that of the PDE4B subtype, which alters downstream cAMP/CREB
signaling, which might be involved in DISC1’s role in neuronal function.
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Introduction
Schizophrenia and depression are common and debilitating mental disorders
characterized by profound emotional and cognitive disturbances (Millar et al., 2007).
The onset is determined by multiple factors, and genetic effects are believed to contribute
to the pathogenesis. Previous studies have shown that Disrupted-in-Schizophrenia 1
(DISC1), produced by chromosomal translocation t (1;11)(q42.1; q 14.3) (Millar et al.,
2000b), enhances the risk of developing mental disorders by 50-fold (Blackwood et al.,
2001). Furthermore, recent studies demonstrate that DISC1 interacts with a number of
proteins in the central nervous system and is involved in compromised cognitive function
and behavioral and anatomical changes linked to psychiatric disease (Miyoshi et al.,
2003; Brandon et al., 2004; Hayashi et al., 2005). These studies indicate that DISC1 is an
important candidate susceptibility gene for mental illness, including schizophrenia,
bipolar disorder and major depression (Millar et al., 2000b; Thomson et al., 2005; Chubb
et al., 2008).
Phosphodiesterase-4 (PDE4), which is another risk factor for mental disorders,
contains four genes (PDE4A-D) and acts to catalyze the hydrolysis of cAMP (Houslay
and Adams, 2003; Millar et al., 2007). The PDE4B subtype was identified as risk factor
in a family diagnosed as schizophrenia and psychotic disorder, who showed an inherited
t(1;16) chromosomal translocation (Millar et al., 2005; Pickard et al., 2007). Studies
revealed that mutations in the fruit fly gene that encodes an orthologous PDE4, i.e., the
dunce gene, showed deficits in synaptic plasticity and learning and memory (Davis et al.,
1995). In addition, PDE4 inhibitors have antidepressant- and antipsychotic-like effects in
animal models (Houslay and Adams, 2003; O'Donnell and Zhang, 2004). Consistent
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with this, mice with deficient in PDE4D or PDE4B show altered behavior in a number of
psychopharmacological tests related to anxiolytic, antidepressant, and antipsychotic
activity (O'Donnell and Zhang, 2004).
Recent studies show that DISC1 modulates PDE4 activity dynamically by releasing
PDE4 in response to increased cAMP levels in a protein kinase A- (PKA) dependent
manner in human neuroblastoma cells (Millar et al., 2005).

Other studies have

demonstrated that DISC1 and PDE4 isoforms are both present at the same neuronspecific regions such as synapses (Kirkpatrick et al., 2006; Clapcote et al., 2007) and are
targeted to particular subcellular compartments (Millar et al., 2005; Lynch et al., 2006;
Mackie et al., 2007).

Both biochemical and clinical studies indicate that the

dysregulation of DISC1-PDE4 interaction is likely to contribute to the symptoms of
severe psychiatric disorders, but the complexities of the DISC1-PDE4 interaction are not
well understood yet.
To examine the association between DISC1 and PDE4, we used a mutant DISC1
mouse strain that carries two termination codons in exons 7 and 8 and a premature
polyadenylation site in intron 8 (Koike et al., 2006). In these DISC1 mutant mice, the
introduced genetic lesion results in the production of a truncated transcript and the
elimination of a major protein isoform of DISC1 (Kvajo et al., 2008). In this study, we
found down-regulated PDE4 activity and enhanced cAMP/pCREB signaling cascade in
DISC1 mutant mice. The reduction of PDE4 activity was accompanied by decreased
expression of PDE4B and high rolipram binding state (HARBS).
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Materials and Methods

Animals
Mutant DISC1 mice were genetically engineered in the laboratory of Joseph Gogos
at Columbia University, and contained the same DISC1 mutation backcrossed in
C57BL/6J, as previously described (Koike et al., 2006). All analyses were performed
using littermates produced by mating of heterozygous mice. All animal procedures were
approved by the Columbia University Institutional Animal Care and Use Committee.

Measurement of Cyclic AMP
For cyclic AMP measurement, hippocampus, striatum and prefrontal cortex were
homogenized in ice-cold 0.1N hydrochloric acid and centrifuged at 13,000 g for 50 min
at 4ºC. Cyclic AMP in the supernatant was measured by ELISA (Assay Designs, Ann
Arbor, MI) (Li et al., 2009).

Western blotting
For phospho-CREB measurement, hippocampus and prefrontal cortex were
homogenized in ice-cold lysis buffer (Upstate, Temecula, CA) and then centrifuged at
10,000g for 30 min at 4C. Solubilized samples were mixed with equal volumes of
Laemmli sample buffer and heated to 100C for 2 minutes. Equal amounts of sample
protein were loaded onto gels for SDS-PAGE. Following separation by electrophoresis,
proteins in the gels were transferred to nitrocellulose membranes, which were incubated
overnight at 4C with primary antibodies against CREB phosphorylated at serine-133
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(Upstate Biotechnology, Lake Placid, NY) and then with Alexa Fluor 680-conjugated
secondary antibody for 30 min at room temperature (Invitrogen, Carlsbad, CA). An
Odyssey Infrared Imaging System (LI-COR Bioscience, Lincoln, NE) was used for
quantifying fluorescence. Treatment-induced changes in phospho-CREB were assessed
within individual gels/immunoblots.

Radioligand Binding Assays
[3H]-Rolipram binding was measured as described previously (Zhao et al., 2003a;
Scharf et al., 2008). Samples containing 200 g of protein were incubated at 30°C in the
presence of 250 l of incubation buffer that containing different concentrations of [3H]rolipram (2–30 nM). Nonspecific binding was determined in the presence of 10 nM
unlabeled Ro 20-1724 [4-3-butoxy-4-methoxybenzyl-2-imidazolidinone] for [3H]rolipram binding. Reactions were stopped by addition of 5 ml of ice-cold binding buffer
after 1 hr and followed by rapid vacuum filtration through glass fiber filters. The filters
were washed twice, and radioactivity measured by liquid scintillation counting.

PDE Activity Assay
The PDE enzyme assay was performed as described previously (Zhang et al., 2008).
Samples were assayed in the presence or absence of 10 uM rolipram. PDE4 activity i.e.
rolipram-sensitivity was calculated by subtracting cAMP hydrolysis in the presence of
rolipram to that in its absence.
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Real Time-Polymerase Chain Reaction RT-PCR
Total RNA was isolated from HPC with TRIzol reagent (Invitrogen, Carlsbad, CA)
according to manufacturer’s instructions, followed by DNase treatment to eliminate
contaminated genomic DNA. Conversion of total RNA into cDNA was performed using
High Capacity cDNA archive kit (Applied Biosystems, Foster City, CA). Real-time PCR
was performed on an ABI PRISM 7300 Detection System Applied Biosystems with
Tagman Universal Mastermix Applied Biosystems. The PDE4B primer was purchased
from Applied Biosystems. The samples were run in triplicate and amplified for 40 cycles
at 50°C for 2 min, 90 °C for 10 min, 95 °C for 15 s, extension 60°C for 1 min. Beta-actin
was used as an endogenous control. The fold difference in expression of target cDNA
was determined using the comparative threshold method as previously described (Livak
and Schmittgen, 2001).

Data Analysis and Statistics
Statistical analysis was performed using one-way analysis of variance followed by
Dunnett’s test. Binding data were analyzed by nonlinear regression (O'Donnell et al.,
1984).

Data are expressed as means  SEM.

significant.
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A p value < 0.05 was considered

Results
Cyclic AMP and pCREB in the hippocampus, prefrontal cortex and striatum of
DISC1 mutant mice.
cAMP levels were significantly increased in the hippocampus, prefrontal cortex and
striatum of homozygous DISC1 mutant mice compared with wild type mice; no
significant changes were observed in the same brain regions of heterozygous DISC1
mutant mice (Fig.3.1).

Consistently, pCREB demonstrated a trend to increase in the

three brain regions of homozygous DISC1 mutant mice, but no changes were observed in
the heterozygous DISC1 mutant mice (Fig.3.2).

PDE4 activity in the hippocampus, prefrontal cortex and striatum of DISC1 mutant
mice.
PDE4 activity was significantly decreased in the hippocampus, prefrontal cortex and
striatum, by 51%, 38% and 70%, respectively, in the homozygous DISC1 mutant mice
compared with wild type mice. In the heterozygous DISC1 mutant mice, PDE4 activity
was decreased by 29%, 23% and 40%, respectively, in the hippocampus, prefrontal
cortex and striatum (Fig.3.3).

PDE4B levels in the hippocampus, prefrontal cortex and striatum of DISC1 mutant
mice.
PDE4B1 was decreased significantly in the hippocampus, prefrontal cortex and
striatum by 59%, 70% and 50%, respectively, in the homozygous mutant DISC1 mice
compared to wild type mice. In heterozygous mice, PDE4B1 was decreased by 11%,
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32% and 38% (Fig.3.4). In addition, PDE4B3 was also decreased significantly by 49%,
52% and 38%, respectively, in the same three brain regions of homozygous mutant
DISC1 mice, and 11%, 8% and 4% in heterozygous DISC1 mutant mice (Fig.3.6).
Similarly, PDE4B4 was decreased by 41%, 40% and 30%, respectively, in the
hippocampus, prefrontal cortex and striatum of homozygous mutant DISC1 mice
compared to wild type mice. Reductions were 15%, 19% and 23% in PDE4B4 levels in
the same brain regions in heterozygous mice (Fig.3.7). No significant changes of
PDE4B2 were observed in DISC1 mutant mice compared to wild type mice (Fig.3.5).
Given the marked reductions in protein levels of PDE4B subtypes in DISC1 mutant
mice, mRNA for PDE4B was measured using real-time RT-PCR.

There were no

significant changes in mRNA for PDE4B in DISC1 mutant mice indicating that the
changes observed in PDE4B expression were post-transcriptional (Fig.3.8).

PDE4D levels in the hippocampus, prefrontal cortex and striatum of DISC1 mutant
mice.
PDE4D3 was reduced by 40% in the hippocampus, but only 15% and 9% in the
prefrontal cortex and striatum of homozygous DISC1 mutant mice compared to wild type
mice.

In heterozygous DISC1 mice, there were 12%, 12% and 7% reductions of

PDE4D3 in these regions, respectively (Fig.3.9). Similarly, PDE4D5 also was reduced in
the hippocampus but not in the prefrontal cortex and striatum of homozygous DISC1
mutant mice. In heterozygous DISC1 mutant mice, PDE4D5 was not reduced
significantly (Fig.3.10).
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PDE4A levels in the hippocampus, prefrontal cortex and striatum of DISC1 mutant
mice.
To reveal whether the mutation of DISC1 affect the PDE4 variant expression, the
subtypes of PDE4A, including PDE4A1 and PDE4A5 were measured. There were no
significant alterations in PDE4A1 in either Hom or Het DSIC1 mutant mice (Fig.3.11).
Similarly, no changes were found in PDE4A5 in the hippocampus, prefrontal cortex or
striatum of mutant DISC1 mice, compared with wild type mice (Fig.3.12).

HARBS levels in the hippocampus, prefrontal cortex and striatum of mutant DISC1
mice.
In order to study whether the mutation of DISC1 alters the HARBS, the index of the
HARBS, [3H]-rolipram binding, was measured in the DISC1 mutant mice. [ 3H]-rolipram
binding were was significantly decreased in the hippocampus, prefrontal cortex and
striatum of DISC1 mutant mice, including Het and Hom group, compared with wild type
mice (Fig.3.13).
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Discussion
DISC1 is involved in multiple neurological signaling cascades, including neuronal
proliferation and extension (Ishizuka et al., 2006; Mackie et al., 2007; Mao et al., 2009).
As one of the most important and particularly noteworthy binding partners of DISC1,
PDE4 is a critical regulator of cAMP. Our studies demonstrate that PDE4 function and
downstream cAMP/pCREB signaling cascade were changed by the mutation of DISC1,
indicating the altered DISC1-PDE4 interaction results in marked changes in cAMP
signaling, most notably that involving PDE4B. Ultimately, this could affect neuronal
progenitor proliferation and neurite extension, promotion of axonal transport and
neuronal radial migration (Porteous et al., 2003; Ross et al., 2006; Camargo et al., 2007;
Shinoda et al., 2007; Taya et al., 2007), and cerebral cortex development (Kamiya et al.,
2005).
PDE4 activity is regulated by phosphorylation in the catalytic domain by
extracellular signal-regulated kinase (ERK) and in the UCR1 by protein kinase A (PKA),
which induces a UCR1-UCR2 interaction (Houslay and Baillie, 2005; Hashimoto et al.,
2006).

Interestingly, recent data have shown that PDE4 activity is dynamically

modulated by DISC1. DISC1 binds to the UCR2 domain, and PDE4B dissociates from
DISC1 in response to increased cAMP (Millar et al., 2005). This indicates that DISC1
could exert its effect by modulating PDE4 activity for a variety of biological responses.
For instance, PDE4 regulates the compartmentalization of cAMP signaling, which is
linked to the learning, memory and mood (O'Donnell and Zhang, 2004; Arguello and
Gogos, 2006).

Therefore, mutation of DISC1 could disrupt the normal complex

interaction, thus interfering with normal learning, memory and cognition, all of which are
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disturbed in patients with schizophrenia.

Our studies have shown that the mutation of

DISC1 decreases PDE4 activity, resulting in increased AMP/pCREB signaling, probably
through the dysregulation of PDE4-DISC1 complex due to the disrupted DISC1 function.
Similarly, in another animal model of schizophrenia, which involves a missense mutation
by changing leucine to proline at position 100, PDE4B activity also is reduced (Clapcote
et al., 2007). Though decreased PDE4 activity might seem contradictory with the model
that proposes PDE4B is released from the DISC1-complex in the high activity form, it is
implied that the reduced association between DISC1-PDE4 induced by mutation might
not be related to the sequence of events that induces PDE4 dissociation from DISC1 and
subsequent activation (Millar et al., 2007). Also, studies of the interaction between
DISC1-PDE4 are complicated by many factors including studies of differences in cell
lines, mouse strains, and methods of DISC1 mutation. Thus, this apparent discrepancy
needs further investigation to be fully understood.
Despite these discrepancies, behavioral data offer more evidence of the interaction
between PDE4 and DISC1. Mice with a DISC1 mutation demonstrate a schizophrenialike phenotype, including hyperactivity and impaired cognition, and these behaviors are
reversed by the treatment with the PDE4 inhibitor, rolipram or an antipsychotic drug
(Marx, 2007).

In addition, these mice with depression-like phenotype respond to

antidepressant treatment in the forced-swim test. Thus, dysfunction of either DISC1 or
PDE4 may compromise a variety of signaling cascades and result in distorted neuronal
development, which underlies the pathogenesis of mental illness. Additionally, DISC1
modulation of cAMP via PDE4, could be another target for treating schizophrenia and
other mental illnesses.
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PDE4 consists of four subtypes including A, B, C and D. PDE4A, PDE4B and
PDE4D are widely expressed throughout the central nervous system, whereas PDE4C is
expressed only at a minimal level in the brain (O'Donnell and Zhang, 2004). Molecular
studies reveal that the association between DISC1 and PDE4 is in a PDE4 isoformdependent manner (Murdoch et al., 2007).

Increased cAMP dissociates PDE4C and

PDE4D from the 100 kDa DISC1, but not the PDE4A or PDE4B isoform; PDE4B does
dissociate from the 71 kDa DISC1 (Millar et al., 2005; Murdoch et al., 2007). This is
explained in part by the number of binding sites between DISC1 and the PDE4 isoforms.
A peptide array strategy shows that DISC1 has five binding sites for PDE4: two sites for
every PDE4 isoform; three more specific sites for PDE4B (Murdoch et al., 2007),
explaining the strong bond between PDE4B and DISC1. In our study, mutation of
DISC1 induced a decrease in PDE4B1, PDE4B3, PDE4B5, but not PDE4B2 in the
prefrontal cortex, hippocampus and striatum, as well as a reduced PDE4D3, PDE4D5
level in the hippocampus, but no changes of PDE4A isoforms. These data indicate that
PDE4B is more involved in the interaction with DISC1 and that PDE4A is less
susceptible to the regulation by altered DISC1. Consistently, the PDE4B1 isoform was
found 50% reduced in lymphoblastoid cell line in patients with mental disorders (Millar
et al., 2005).

PDE4B was also found associated with affective disorders and

schizophrenia (Pickard et al., 2005).
PDE4D is highly expressed in the hippocampus and the reduction of PDE4D in this
region indicates it to have a primary role in the regulation of cAMP signaling; however,
PDE4D is mainly regulated by phosphorylation (O'Donnell and Zhang, 2004).
Interestingly, other animal models of schizophrenia, which have mutations from
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glutamine to leucine at position 31 (31L) or from leucine to proline at position 100
(100P), decrease binding between DISC1 and PDE4B, particularly for the long isoforms
PDE4B1 and PDE4B3 (Clapcote et al., 2007). Clinical studies showed various results
due to limited sample resources and variations in lifetime drug treatment in patients. One
study showed PDE4B (PDE4B1, PDE4B2, PDE4B3 and PDE4B4) was decreased in the
cerebella of patients with autism (Braun et al., 2007).

Another study showed PDE4A

was reduced in cerebella of patients with bipolar disorder, but not in the patients with
schizophrenia or major depression (Fatemi et al., 2008).
One complexity in the understanding of PDE4 is the high-affinity and low-affinity
rolipram binding states (HARBS and LARBS). It was first described that [3H]-rolipram
bound to brain tissues with high affinity, while to peripheral tissues with low affinity
(Schneider et al., 1986). Further studies using recombinant PDE4A revealed that [ 3H]rolipram exhibited two distinct affinities with 500-fold differences in Ki (Jacobitz et al.,
1996). Interestingly, PDE4 is expressed throughout the body, but HARBS is found in the
CNS but not in peripheral tissues. Consistent with its location, current studies indicat e
that the CNS effects of PDE4 are mediated mainly by HARBS (O'Donnell and Zhang,
2004).

In our study, HARBS was decreased in three brain regions of DISC1 mutant

mice, including the hippocampus, prefrontal cortex and striatum. Simultaneously, PDE4
activity was also reduced in the same regions, suggesting decreased HARBS might
contribute to the reduced PDE4 activity. Previous studies have shown that repeated
treatment with desipramine or fluoxetine increases HARBS in cerebral cortex and
hippocampus (Zhao et al., 2003a), suggesting an alteration in the component of the
signaling cascade involving PDE4.
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In a summary, DISC1 modulates cAMP/pCREB signaling via an interaction with
PDE4.

DISC1 mutation up-regulates cAMP/pCREB signaling via decreased PDE4

activity, mainly due to reduced PDE4B and PDE4D variants, while simultaneously
decreases HARBS. The DISC1-PDE4 interaction may offer a means to selectively
reduce the activity of particular PDE4 subtypes, which may offer a unique
pharmacological profile for the treatment of psychiatric illnesses.
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Figure Legends

Fig. 3.1. Cyclic AMP levels in the hippocampus, prefrontal cortex and striatum of wild
type (Wt) and DISC1 mutant mice. Cyclic AMP was increased significantly in the
hippocampus (A), prefrontal cortex (B) and striatum (C) of homozygous (Hom) DISC1
mutant mice compared with wild type mice. Values are means ± SEM, n=3-4 per group.
*P<0.05 vs. corresponding control.

Fig. 3.2. Phospho-CREB levels in the hippocampus, prefrontal cortex and striatum of
wild type (Wt) and DISC1 mutant mice. Phospho-CREB was significantly increased in
the prefrontal cortex (B) of homozygous (Hom) DISC1 mutant mice compared with wild
type mice.

A trend toward an increase in phospho-CREB was observed in the

hippocampus (A) and striatum (C) in homozygous (Hom) DISC1 mutant mice. Values
are means ± SEM, n=3-4 per group. *P<0.05 vs. corresponding control.

Fig. 3.3. PDE4 activity in the hippocampus, prefrontal cortex and striatum of wild type
(Wt) and DISC1 mutant mice. PDE4 activity was significantly decreased in the
hippocampus (A), prefrontal cortex (B) and striatum (C) of homozygous (Hom) DISC1
mutant mice compared to wild type mice. In addition, PDE4 activity was also decreased
in the striatum of heterozygous (Het) DISC1 mutant mice. Values are means ± SEM,
n=3-4 per group. **P<0.01, *P<0.05 vs. corresponding control.
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Fig. 3.4. PDE4B1 levels in the hippocampus, prefrontal cortex and striatum of wild type
(Wt) and DISC1 mutant mice. PDE4B1 was decreased in the hippocampus (A),
prefrontal cortex (B) and striatum (C) of homozygous (Hom) DISC1 mutant mice
compared with wild type mice. There was no significant change of PDE4B1 in the
heterozygous (Het) mice. Values are means ± SEM, n=3-4 per group. *P<0.05 vs.
corresponding control.

Fig. 3.5. PDE4B2 levels in the hippocampus, prefrontal cortex and striatum of wild type
(Wt) and DISC1 mutant mice. PDE4B2 showed a trend toward an increase in
hippocampus (A), prefrontal cortex (B) or striatum (C) of homozygous (Hom) DISC1
mutant mice compared with wild type mice. No changes were found in heterozygous
(Het) mice. Values are means ± SEM, n=3-4 per group.

Fig. 3.6. PDE4B3 levels in the hippocampus, prefrontal cortex and striatum of wild type
(Wt) and DISC1 mutant mice. PDE4B3 was decreased in the hippocampus (A),
prefrontal cortex (B) and striatum (C) of homozygous (Hom) DISC1 mutant mice
compared with wild type mice. There were no changes in PDE4B3 in the heterozygous
(Het) mice. Values are means ± SEM, n=3-4 per group. *P<0.05 vs. corresponding
control.

Fig. 3.7. PDE4B4 levels in the hippocampus, prefrontal cortex and striatum of wild type
(Wt) and DISC1mutant mice.

PDE4B4 was decreased in the hippocampus (A),

prefrontal cortex (B), but not in the striatum (C) of homozygous (Hom) DISC1 mutant
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mice compared with wild type mice. Values are means ± SEM, n=3-4 per group.
**P<0.01, *P<0.05 vs. corresponding control.

Fig. 3.8. PDE4B mRNA levels in the hippocampus, prefrontal cortex and striatum of
wild type (Wt) and DISC1mutant mice. No significant changes were observed in the
DISC1 mutant mice compared with wild type mice. Values are means ± SEM, n=3-4 per
group.

Fig. 3.9. PDE4D3 levels in the hippocampus, prefrontal cortex and striatum of wild type
(Wt) and DISC1 mutant mice. PDE4D3 was decreased in the hippocampus (A), but not
prefrontal cortex (B) or striatum (C) of homozygous (Hom) mice compared to wild type
mice. Values are means ± SEM, n=3-4 per group. **P<0.01 vs. corresponding control.

Fig. 3.10. PDE4D5 levels in the hippocampus, prefrontal cortex and striatum of wild type
(Wt) and DISC1 mutant mice. PDE4D5 was changed in the hippocampus (A), but not in
the prefrontal cortex (B) and striatum (C) of homozygous (Hom) DISC1 mutant mice.
Values are means ± SEM, n=3-4 per group. *P<0.05 vs. corresponding control.

Fig. 3.11. PDE4A1 levels in the hippocampus, prefrontal cortex and striatum of wild type
(Wt) and DISC1 mutant mice. PDE4A1 was not changed in the hippocampus (A),
prefrontal cortex (B) or striatum (C) of DISC1 mutant mice compared with wild type
mice. Values are means ± SEM, n=3-4 per group.
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Fig. 3.12. PDE4A5 levels in the hippocampus, prefrontal cortex and striatum of wild type
(Wt) and DISC1 mutant mice. PDE4A5 was not changed in the hippocampus (A),
prefrontal cortex (B) or striatum (C) of DISC1 mutant mice compared with wild type
mice. Values are means ± SEM, n=3-4 per group.

Fig. 3.13. HARBS levels in the hippocampus, prefrontal cortex and striatum of wild type
(Wt) and DISC1 mutant mice. HARBS was decreased in the hippocampus (A), prefrontal
cortex (B) and striatum (C) in the DISC1 mutant mice compared with wild type mice.
Values are means ± SEM, n=3-4 per group. **P<0.01, *P<0.05 vs. corresponding
control.
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Figure 3.1
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Figure 3.4
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Figure 3.9
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Figure 3.12
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Figure 3.13
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Chapter 4

Overall discussion and conclusion
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PDE4 plays a vital role in maintaining normal function of the central nervous system
by modulating cAMP levels.

Dysfunction of PDE4 contributes to the changes in

cognitive function and impaired memory related to the symptoms in psychiatric patients
(O'Donnell and Zhang, 2004). Previous studies have indicated that the specific PDE4
inhibitor rolipram has potent antidepressant effects in both animal models and patients
with depression. However, despite the initial promise of PDE4 inhibitors as potent
antidepressants, its clinical utility has not advanced significantly (O'Donnell and Zhang,
2004). This is due to an incomplete understanding of the function of PDE4 subtypes and
the HARBS and LARBS in PDE4-mediated antidepressant-like effects. Therefore, it is
of interest to know how HARBS and LARBS mediate their different pharmacological
effects in the central nervous system. In the present study, we examined the differences
in the effects of three PDE4 inhibitors, which have varying affinities for HARBS and
LABRS, on cAMP signaling, hippocampal neurogenesis, immobility in forced-swim test,
and PDE4 subtypes and the HARBS in DISC1 mutant mice.
To test the antidepressant-like effects in forced-swim test, both acute and repeated
treatment were used. Acute treatment at higher doses did not produce any antidepressantlike effects as evidenced by an increase trend in immobility time likely due to the
sedative effects. Repeated treatment with PDE4 inhibitors for 16 days decreased
immobility significantly, compared with control groups.

Compared with CDP840,

which mainly interacts with the LARBS, lower doses of rolipram and piclamilast exerted
greater effects in the forced-swim test.
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Compared with rolipram, piclamilast is about 1000-fold more potent for binding to
the LARBS and 40-fold more potent for binding to the HARBS (Zhao et al., 2003b). By
contrast, CDP840 has a modest affinity for the LARBS and lower affinity to the HARBS.
Consistent with their functions, HARBS is mainly located in the central nervous system,
while LARBS in the peripheral tissues and the brain.

In addition, antidepressant

treatment increased HARBS but not LARBS in the brain (Zhao et al., 2003a). Taken
together, the results suggest that the antidepressant-like effects of the PDE4 inhibitors are
mediated predominantly by the HARBS.
In order to determine whether HARBS or LARBS is involved in the cAMP signaling
and hippocampal neurogenesis, the differences in the effects of PDE4 inhibitors on
cAMP/pCREB and neuronal proliferation were studied. Repeated treatment with three
PDE4 inhibitors increased cAMP/pCREB signaling, but only rolipram and piclamilast
enhanced hippocampal proliferation and survival.

By contrast, CDP840, which has

higher affinity to LARBS, failed to produce similar effects. All three compounds
demonstrated antidepressant-like effects in forced-swim test, but not all of them enhanced
hippocampal neurogenesis, indicating enhanced hippocampal neurogenesis is not
necessary for the PDE4-inhibitor mediated antidepressant-like effects. In addition,
HARBS seems to be more involved in the hippocampal neurogenesis, when compared
with LARBS.

These results suggest a close association between the HARBS and

increased cyclic AMP signaling, neurogenesis, and antidepressant-like effects on
behavior. Since side effects, including nausea and sedation, appeared to be mediated by
the HARBS as well (O'Donnell and Zhang, 2004), simply modifying the affinity of PDE4
inhibitors for the HARBS might not be enough to develop better medication with fewer
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side effects.

However, other alternative approaches, such as targeting the specific

subtype of PDE4, might produce more desired pharmacological effects.
To determine the effects of a mutation of DISC1, one of the most important binding
partners to PDE4, the PDE4 activity and PDE4 splice variants and HARBS were studied
in the mouse strain carrying truncated DISC1. The mutation of DISC1 decreased PDE4
activity in three brain regions, hippocampus, prefrontal cortex and striatum, as well as
increasing cAMP/pCREB levels. Similarly, previous studies have reported decreased
binding of the mutant DISC1 with PDE4B in over-expression systems, coupled with
decreased activity of PDE4 (Millar et al., 2005). In another DISC1 mutant line Q31L,
PDE4 activity was also decreased by 50%. When these mice were treated with rolipram,
they seemed resistant (Clapcote et al., 2007). Rolipram resistance and decreased PDE4
activity suggest a strong correlation between an elevated cAMP signaling and the
compromised DISC/PDE4 interaction. Currently, compelling biological evidence has
shown that disrupted cAMP signaling mediated by the dysfunction of DISC1/PDE4B
induces abnormal neurite outgrowth, axonal transport, neuronal migration (Porteous et
al., 2003; Ross et al., 2006; Camargo et al., 2007; Shinoda et al., 2007; Taya et al., 2007)
and thus contributes to compromised memory and learning function, and even psychotic
symptoms in patients with schizophrenia (Pletnikov et al., 2007).
Though studies show that mutation of DISC1 compromised PDE4 function, it is still
far from clear which subtype of PDE4 is mainly affected in the central nervous system.
Molecular studies have demonstrated that DISC1 contains 2 binding sites for PDE4, 3
more specific binding sites for PDE4B (Millar et al., 2005; Murdoch et al., 2007).
However, it is not clear whether DISC1 works the same way in the human central
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nervous system.

In our DISC1 mutant mice, PDE4 splice variant levels, such as

PDE4B1, B3 and B4, were decreased in three brain regions, and PDE4D were reduced
only in the hippocampus, while no changes in PDE4A splice variants were observed.
This suggests that among the PDE4 subtypes, PDE4B is a main binding partner for
DISC1 and appears to be much more involved in the DISC1/PDE4 interaction.
Interestingly, among the PDE4B splice variants, PDE4B2 was not decreased
significantly. This may due to its structure as a short form of PDE4, which lacks of a
UCR1 region. In addition, PDE4D was only altered in the hippocampus, suggesting its
function is also brain region-dependent.

In addition to studies showing differential

regulation of PDE4 subtypes after antidepressant treatment, it appears that each PDE4
splice variants plays a variety of roles in the response to antidepressant treatment and in
the development of mental disorders.

However, due to the lack of specific PDE4

subtype inhibitors, the exact function of PDE4 subtypes needs more research to be fully
understood.
In order to determine whether DISC1 mutation affects the HARBS, [3H]-rolipram
binding, which is used to label HARBS, was performed.

In both homogenous and

heterogeneous DISC1 mutant mice, the HARBS was decreased significantly compared
with wild type mice. This suggests that the HARBS might be more sensitive to the
dysfunction of DISC1 or more involved in the DISC1/PDE4 interaction. As certain
PDE4 subtypes were also reduced in the same brain regions, it is very possible that most
of these subtypes of PDE4 exist as HARBS in the CNS. It is also likely that the mutant
DISC1 binds to any unknown cellular factors, and thus alters the conformation of PDE4,
facilitating the transformation from HARBS to LARBS.
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Currently, there are several animal models of schizophrenia. In the DISC1 mutant
mice used in the present study, mutation yielded a truncated DISC1 protein, which was
rapidly degraded. Compared with wild type mice, these mice demonstrate deficits in
working memory tasks (Koike et al., 2006; Kvajo et al., 2008), consistent with previous
studies linking DISC1/PDE4 to cognition function.

In other animal models, which

express a dominant-negative mutant DISC1, abnormal spatial memory was also observed
(Pletnikov et al., 2008). Other animal models with different DISC1 point mutations
showed schizophrenia-like or depressive-like phenotypes respectively (Clapcote et al.,
2007).

Though these animal models revealed different behavioral abnormalities, it

appears that these mouse models concur with the human genetic studies. It suggests that
there are likely several routes by which DISC1 can perturb brain function leading to
characteristics of human mental disorders. It is difficult to expect the phenotypes in the
animal models of schizophrenia because it is believed to be the culmination of both
genetic and environmentally elicited changes.

Thus, these mouse models have

advantages for the studying of both genetic effects and environmental impact for
psychiatric disorders (Clapcote et al., 2007).
Collectively, these data characterize the function of HABRS on cAMP/pCREB
signaling, hippocampal neurogenesis and its corresponding behaviors, as well as the
interaction between DISC1 and PDE4. They shed light on the pharmacological effects of
the HARBS and the complexity of DISC1/PDE4. However, the role of the HARBS in
the central nervous system is still relatively unknown, and remains an interesting question
for the future. Characterizing the alteration of downstream effectors of DISC1/PDE4
remains an important area of investigation and could provide us a better understanding of
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pathogenesis of mental disorders.

It is intriguing that DISC1 interacts with PDE4,

regulating cAMP signaling and altering PDE4 subtype levels.

This suggests

compromised cAMP signaling induced by the dysfunction of DISC1/PDE4 is critical for
the development of mental disorder, and thus it will be very important to determine if the
DISC1/PDE4 pathway is particularly vulnerable in neuropsychiatric disorders.
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